Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Aug 31;228(Suppl 2):S77-S82.
doi: 10.1093/infdis/jiad246.

ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients

Judith S Currier  1 , Carlee Moser  2 , Joseph J Eron  3 , Kara W Chew  1 , Davey M Smith  4 , Arzhang Cyrus Javan  5 , David Alain Wohl  3 , Eric S Daar  6 , Michael D Hughes  2 ; ACTIV-2/A5401 Study Team
Collaborators, Affiliations
Clinical Trial

ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients

Judith S Currier et al. J Infect Dis. .

Abstract

Clinical Trials Registration ClinicalTrials.gov Identifier: NCT04518410.

Keywords: ACTIV-2; COVID-19; clinical trial; monoclonal antibodies.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. JSC has consulted for Merck and Company. KWC reports research funding to the institution from Merck Sharp & Dohme and is a consultant for Pardes Biosciences. CM participated on a Data Safety Monitoring Board for the BONE STAR study. JJE is an ad hoc consultant to GSK/VIR and data monitoring committee chair for Adagio Phase III studies. DMS has consulted for Evidera, Fluxergy, Kiadis, Linear Therapies, Matrix BioMed, Arena Pharmaceuticals, VxBiosciences, Model Medicines, Bayer Pharmaceuticals, Signant Health, and Brio Clinical. DAW has received funding to the institution to support research and honoraria for advisory boards and consulting from Gilead Sciences. ESD receives consulting fees from Gilead Sciences, Merck, and GSK/ViiV and research support through the institution from Gilead Sciences and GSK/ViiV. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
ACTIV-2 accrual timeline.
See this image and copyright information in PMC

References

    1. Collins FS, Stoffels P. Accelerating COVID-19 therapeutic interventions and vaccines (ACTIV): an unprecedented partnership for unprecedented times. JAMA 2020; 323:2455–7. - PubMed
    1. LaVange L, Adam SJ, Currier JS, et al. Accelerating COVID-19 therapeutic interventions and vaccines (ACTIV): designing master protocols for evaluation of candidate COVID-19 therapeutics. Ann Intern Med 2021; 174:1293–300. - PMC - PubMed
    1. Grobler JA, Anderson AS, Fernandes P, et al. Accelerated preclinical paths to support rapid development of COVID-19 therapeutics. Cell Host Microbe 2020; 28:638–45. - PMC - PubMed
    1. Choudhary MC, Chew KW, Deo R, et al. Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial. Nat Microbiol 2022; 7:1906–17. - PMC - PubMed
    1. Boucau J, Chew KW, Choudhary MC, et al. Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection. Cell Rep Med 2022; 3:100678. - PMC - PubMed

Publication types

Substances

Associated data